About Roche in Switzerland
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry seven years in a row by the Dow Jones Sustainability Indices.
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
A leader around the world and at home
- Last year Roche employed some 13,000 employees from over 90 countries in Switzerland. This makes Switzerland one of Roche’s three largest locations in the world, along with the United States and Germany.
- Since 2010, seven innovative products and indications from Roche have been approved in the accelerated process by Swissmedic.
- In Switzerland Roche has 10 cancer medications, many of which improve patients’ chances of survival.
- Roche is one of the five most valuable Swiss companies by market capitalisation on the Swiss stock exchange.
- In the past three years, Roche has invested some 1.25 billion francs in Switzerland, of which around 1 billion were invested in Basel and Kaiseraugst and 250 million in Rotkreuz.
- Four out of five people with diabetes who use insulin pumps in Switzerland rely on a product from Roche.
- Roche is the largest provider of medications for hospitals in its home market.
- About one-quarter of Roche’s global research and development spending occurs in Switzerland.
- Numerous alliances and scientific partnerships exist between Roche and academic institutes in Switzerland.
- Roche is among the three leading research institutions in Switzerland, with some 3,500 employees in the areas of pharmacological and diagnostics research and development.
- Since 2000, Roche has conducted more than 100 clinical studies of medications with well over 2,000 patients.
- Roche is one of the world’s largest investors in research and development. In Switzerland alone, last year Roche spent 2.4 billion Swiss francs.
- Roche is among the largest private employers in Switzerland and, with over 390 trainees in 14 different professions, one of the country’s largest providers of vocational training.
- The descendants of the founder of Roche make up the majority of Roche shareholders. Hardly any other major company in the world has such a stable and strong ownership structure.
There are currently no jobs.